First Time Loading...

Mirati Therapeutics Inc
NASDAQ:MRTX

Watchlist Manager
Mirati Therapeutics Inc Logo
Mirati Therapeutics Inc
NASDAQ:MRTX
Watchlist
Price: 58.7 USD Market Closed
Updated: Apr 16, 2024

Intrinsic Value

MRTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. [ Read More ]

The intrinsic value of one MRTX stock under the Base Case scenario is 27.73 USD. Compared to the current market price of 58.7 USD, Mirati Therapeutics Inc is Overvalued by 53%.

Key Points:
MRTX Intrinsic Value
Base Case
27.73 USD
Overvaluation 53%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mirati Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MRTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Mirati Therapeutics Inc

Provide an overview of the primary business activities
of Mirati Therapeutics Inc.

What unique competitive advantages
does Mirati Therapeutics Inc hold over its rivals?

What risks and challenges
does Mirati Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Mirati Therapeutics Inc recently?

Summarize the latest earnings call
of Mirati Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mirati Therapeutics Inc.

Provide P/S
for Mirati Therapeutics Inc.

Provide P/E
for Mirati Therapeutics Inc.

Provide P/OCF
for Mirati Therapeutics Inc.

Provide P/FCFE
for Mirati Therapeutics Inc.

Provide P/B
for Mirati Therapeutics Inc.

Provide EV/S
for Mirati Therapeutics Inc.

Provide EV/GP
for Mirati Therapeutics Inc.

Provide EV/EBITDA
for Mirati Therapeutics Inc.

Provide EV/EBIT
for Mirati Therapeutics Inc.

Provide EV/OCF
for Mirati Therapeutics Inc.

Provide EV/FCFF
for Mirati Therapeutics Inc.

Provide EV/IC
for Mirati Therapeutics Inc.

Show me price targets
for Mirati Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Mirati Therapeutics Inc?

How accurate were the past Revenue estimates
for Mirati Therapeutics Inc?

What are the Net Income projections
for Mirati Therapeutics Inc?

How accurate were the past Net Income estimates
for Mirati Therapeutics Inc?

What are the EPS projections
for Mirati Therapeutics Inc?

How accurate were the past EPS estimates
for Mirati Therapeutics Inc?

What are the EBIT projections
for Mirati Therapeutics Inc?

How accurate were the past EBIT estimates
for Mirati Therapeutics Inc?

Compare the revenue forecasts
for Mirati Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mirati Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mirati Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mirati Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Mirati Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Mirati Therapeutics Inc with its peers.

Analyze the financial leverage
of Mirati Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Mirati Therapeutics Inc.

Provide ROE
for Mirati Therapeutics Inc.

Provide ROA
for Mirati Therapeutics Inc.

Provide ROIC
for Mirati Therapeutics Inc.

Provide ROCE
for Mirati Therapeutics Inc.

Provide Gross Margin
for Mirati Therapeutics Inc.

Provide Operating Margin
for Mirati Therapeutics Inc.

Provide Net Margin
for Mirati Therapeutics Inc.

Provide FCF Margin
for Mirati Therapeutics Inc.

Show all solvency ratios
for Mirati Therapeutics Inc.

Provide D/E Ratio
for Mirati Therapeutics Inc.

Provide D/A Ratio
for Mirati Therapeutics Inc.

Provide Interest Coverage Ratio
for Mirati Therapeutics Inc.

Provide Altman Z-Score Ratio
for Mirati Therapeutics Inc.

Provide Quick Ratio
for Mirati Therapeutics Inc.

Provide Current Ratio
for Mirati Therapeutics Inc.

Provide Cash Ratio
for Mirati Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Mirati Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Mirati Therapeutics Inc?

What is the current Free Cash Flow
of Mirati Therapeutics Inc?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
Mirati Therapeutics Inc

Current Assets 1B
Cash & Short-Term Investments 976.4m
Receivables 18m
Other Current Assets 41.7m
Non-Current Assets 93.6m
Long-Term Investments 27.8m
PP&E 51.1m
Intangibles 14.1m
Other Non-Current Assets 600k
Current Liabilities 137.4m
Accounts Payable 38m
Accrued Liabilities 99.4m
Non-Current Liabilities 45.8m
Other Non-Current Liabilities 45.8m
Efficiency

Earnings Waterfall
Mirati Therapeutics Inc

Revenue
38.2m USD
Cost of Revenue
-4.4m USD
Gross Profit
33.8m USD
Operating Expenses
-798.7m USD
Operating Income
-764.9m USD
Other Expenses
39m USD
Net Income
-725.9m USD

Free Cash Flow Analysis
Mirati Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MRTX Profitability Score
Profitability Due Diligence

Mirati Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
30/100
Profitability
Score

Mirati Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

MRTX Solvency Score
Solvency Due Diligence

Mirati Therapeutics Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
77/100
Solvency
Score

Mirati Therapeutics Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRTX Price Targets Summary
Mirati Therapeutics Inc

Wall Street analysts forecast MRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRTX is 64.5 USD .

Lowest
Price Target
Not Available
Average
Price Target
64.5 USD
10% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MRTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MRTX Price
Mirati Therapeutics Inc

1M 1M
-
6M 6M
+5%
1Y 1Y
+39%
3Y 3Y
-63%
5Y 5Y
-8%
10Y 10Y
+212%
Annual Price Range
58.7
52w Low
27.8
52w High
62.38
Price Metrics
Average Annual Return 18.02%
Standard Deviation of Annual Returns 80.62%
Max Drawdown -88%
Shares Statistics
Market Capitalization 4.1B USD
Shares Outstanding 70 147 696
Percentage of Shares Shorted 7.53%

MRTX Return Decomposition
Main factors of price return

What is price return decomposition?

MRTX News

Other Videos

Last Important Events
Mirati Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Mirati Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Mirati Therapeutics Inc Logo
Mirati Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.1B USD

Dividend Yield

0%

Description

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 413 full-time employees. The company went IPO on 2013-07-12. The company is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. The company also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.

Contact

CALIFORNIA
San Diego
3545 Cray Court
+18583323410.0
https://www.mirati.com/

IPO

2013-07-12

Employees

413

Officers

Founder, President, CEO & Director
Dr. Charles M. Baum M.D., Ph.D.
Executive VP & Chief Scientific Officer
Dr. James G. Christensen Ph.D.
Executive VP & Chief Medical Officer
Dr. Alan Bart Sandler M.D.
Chief Financial Officer
Mr. Aaron Ondrey
Chief Accounting Officer, Principal Accounting Officer & VP of Finance
Ms. Betsy Gelfand CPA
Chief Legal Officer & Corporate Secretary
Mr. John B. Moriarty Jr., J.D.
Show More
Chief Compliance Officer
Mr. Peter Lee
Chief People Officer
Mr. Michael E. Paolucci
Chief Commercial Officer
Mr. Benjamin J. Hickey M.B.A.
VP & Head of Medical Affairs
Dr. Kelly Covello Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MRTX stock?

The intrinsic value of one MRTX stock under the Base Case scenario is 27.73 USD.

Is MRTX stock undervalued or overvalued?

Compared to the current market price of 58.7 USD, Mirati Therapeutics Inc is Overvalued by 53%.